Company & Sponsor Intelligence
NeuroDerm Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries2
Therapeutic footprint
adhdparkinsons
Indexed studies
NCT01103011Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
parkinsons · IsraelPHASE1
parkinsons · IsraelPHASE1
NCT02577523A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT01174355A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
adhd · IsraelPHASE1, PHASE2
adhd · IsraelPHASE1, PHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →